ClinicalTrials.gg
CompletedNCT04990245APOLLOUpdated Aug 4, 2021

pAtient rePorted Outcomes Linked With histoLogy in Patients With uLcerative cOlitis

An observational study in Ulcerative Colitis, sponsored by Imelda GI Clinical Research Center. Completed at 1 site in Belgium. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-04.

Sponsored by Imelda GI Clinical Research Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
86
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.

Enrollment
18th of 19
86 · median 280
Started
2020
with 6 others
Observational
19 of 187
5 open now
Registered
136th of 187
by date

Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one is the 18th largest by enrollment of the 19 observational ones that give a count, is one of 7 that started in 2020, is one of 19 observational ones, and was the 136th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Colitis, Ulcerative with a site in Belgium, or all of them as a file.
02

Study summary

Background and rationale:

In ulcerative colitis, treating beyond endoscopic healing has shown a reduction of relapse and hospitalization, pushing for histological remission in daily clinical practice.1 However, very little is known on how histological remission is associated with patient reported outcomes (PROMs).2,3 In recent years, several questionnaires have been developed to assess what really matters to patients: symptoms and the burden UC exerts on them.4 As PROMs are getting more and more attention during drug development programs and drug approval by international organizations, including FDA and EMA, the link between objective outcome measures (endoscopic, histological, biochemical) and PROMs should therefore be better characterized.

Objectives and design:

To investigate prospectively the association of patient reported outcomes (PROMs) and biochemical, endoscopic and histological outcome measures in patients with ulcerative colitis.

Read the detailed description

After informed consent, patients will undergo endoscopic assessment evaluating endoscopic disease activity using established scoring systems

  • Mayo endoscopic sub-score5
  • Ulcerative Colitis Endoscopic Index of Severity [UCEIS]6 All endoscopic assessments will be recorded, allowing blinded scoring by independent endoscopists afterwards. Study protocol APOLLO - 2 During endoscopy, colonic biopsies will be taken according to standard of care from the most inflamed area of the colon and normal area if applicable, 0-60cm from the anal verge. All biopsies will be scored histologically using the Nancy Index.7 During the same study visit, clinical symptoms (Simple clinical colitis activity index [SCCAI]) and patient reported outcomes (PROMs) will be evaluated digitally using validated scoring systems8
  • IBD disk
  • PRO-2
  • Visual Analogue Scale
  • IBD control in case of non-remission Finally, patients will be biochemically (C-reactive protein, hemoglobin, albumin) evaluated, including measurement of drug level (infliximab, adalimumab, vedolizumab) in case of ongoing exposure to biological agents. All evaluations are part of standard-of-care. Definitions
  • Endoscopic remission: Mayo endoscopic sub-score 0 AND UCEIS 0
  • Endoscopic response according to

    • Mayo score: decrease in Mayo endoscopic sub-score ≥ 1
    • UCEIS: decrease in UCEIS ≥ 2
  • Endoscopic improvement: Mayo endoscopic sub-score 1
  • Histological remission: Nancy histological index 0
  • Absence of active/acute histological inflammation: Nancy histological index 0-1
  • Histological response: Nancy histological index > 1
  • PRO2 remission: stool frequency ≤ 1 (absolute stool frequency ≤ 3 OR 1-2 stools more than usual) AND rectal bleeding score of 0 (average of 3 days prior to endoscopy)
  • IBD disk remission per item:

    • Abdominal pain
    • Regulating defecation
    • Interpersonal interactions
    • Education and work
    • Sleep
    • Energy
    • Emotions
    • Body Image
    • Sexual function
    • Joint pain
03

Conditions studied

  • Ulcerative Colitis

Keywords

  • ulcerative colitis
  • patient reported outcomes
  • histological scoring
  • disability
  • inflammatory bowel disease
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with ulcerative colitis and planned endoscopy as part of routine care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients with ulcerative colitis (≥ 16 years) undergoing planned endoscopic assessment as part of standard of care between 01.07.2020 and 30.06.2021. Evidence of a personally signed and dated document (ICF) indicating that the subject has been informed of all aspects of the study.

Exclusion criteria

EXCLUSION CRITERIA:

Subjects with a diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or Crohn's disease.

Subjects with clinical findings suggestive of CD (e.g. fistulae, granulomas on ) are also excluded. Similar data collection within 8 weeks prior to endoscopic assessment

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
86 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • patients with ulcerative colitis

    patients with ulcerative colitis and planned endoscopy as part of routine care

    Diagnostic Test: endoscopic biopsies

Interventions

  • Diagnostic testendoscopic biopsies

    patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests

06

What researchers measure

Primary outcomes

  1. correlation between histological disease activity and disability

    histological activity is based on the Nancy score, disability is based on the IBD disk

    Time frame: 1 day

Secondary outcomes

  1. correlation between histological disease activity and patient reported outcomes

    histological activity is based on the Nancy score, PRO is based on the SCCAI

    Time frame: 1 day

  2. correlation between histological disease activity and patient reported outcomes

    histological activity is based on the Nancy score, PRO is based on the VAS

    Time frame: 1 day

  3. correlation between histological disease activity and patient reported outcomes

    histological activity is based on the Nancy score, PRO is based on the PRO-2

    Time frame: 1 day

  4. correlation between histological disease activity and endoscopic disease activity

    histological activity is based on the Nancy score, endoscopic disease activityis based on the Mayo endoscopic subscore

    Time frame: 1 day

  5. correlation between histological disease activity and endoscopic disease activity

    histological activity is based on the Nancy score, endoscopic disease activity is based on the UCEIS

    Time frame: 1 day

  6. correlation between histological disease activity and biomarkers

    histological activity is based on the Nancy score, biomarkers (CRP, hemoglobine, albumin)

    Time frame: 1 day

Other outcomes

  1. correlation between histological disease activity and patient reported outcomes

    histological activity is based on the Nancy score, disability is based on the IBD control in case of non remission

    Time frame: 1 day

07

Study locations

1 site
  • Imelda GI clinical research center
    Bonheiden, 2820, Belgium
08

References and documents

Publications

  • Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):1-2. doi: 10.1038/s41575-019-0211-1. No abstract available. PubMed 31520081 ↗
  • Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017 Dec;66(12):2063-2068. doi: 10.1136/gutjnl-2016-312307. Epub 2016 Sep 2. PubMed 27590995 ↗
  • Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, Milovanovic T, Djuranovic S, Jovanovic I, Rajic S, Stojkovic M, Milicic B, Kmezic S, Oluic B, Aleksic M, Pavlovic Markovic A, Popovic D. Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients. Gastroenterol Res Pract. 2020 Apr 2;2020:2065383. doi: 10.1155/2020/2065383. eCollection 2020. PubMed 32328091 ↗
  • de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ. Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review. Clin Gastroenterol Hepatol. 2018 May;16(5):648-663.e3. doi: 10.1016/j.cgh.2017.10.019. Epub 2017 Oct 23. PubMed 29074448 ↗
  • Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. Erratum In: N Engl J Med. 2006 May 18;354(20):2200. PubMed 16339095 ↗
  • Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov;145(5):987-95. doi: 10.1053/j.gastro.2013.07.024. Epub 2013 Jul 25. PubMed 23891974 ↗
  • Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Development and validation of the Nancy histological index for UC. Gut. 2017 Jan;66(1):43-49. doi: 10.1136/gutjnl-2015-310187. Epub 2015 Oct 13. PubMed 26464414 ↗
  • Bossuyt P, Hoefkens E, Pouillon L. Prime Time Was Yesterday for Patient-reported Outcomes in Daily Care of Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1839. doi: 10.1016/j.cgh.2018.05.029. No abstract available. PubMed 30343866 ↗

Individual participant data

Plan to share: Undecided — up on request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jul 2021, 12 months.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's 12 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 4, 2021
StartActual
Jul 1, 2020
Primary completionActual
Jul 28, 2021
CompletionActual
Jul 28, 2021
Last update
Aug 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04990245
Lead sponsor
Imelda GI Clinical Research Center
Responsible party
Sponsor
First posted
Aug 4, 2021
Start date
Jul 1, 2020
Primary completion
Jul 28, 2021
Completion
Jul 28, 2021
Last update
Aug 4, 2021

Study contacts

Peter Bossuyt, MD
principal investigator · Imelda general hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion